September 1, 2010
Author(s)
Stephen T. Stern, Jennifer B. Hall, Lee L. Yu, Laura J. Wood, Giulio F. Paciotti, Lawrence Tamarkin, Stephen E. Long, Scott E. McNeil
There are many important considerations during preclinical development of cancer nanomedicines, including: 1) unique aspects of animal study design; 2) the difficulties in evaluating biological potency, especially for complex formulations; 3) the